Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 1998. Start Trial.
Date Value
September 30, 2026 252.91M
June 30, 2026 252.91M
March 31, 2026 249.30M
December 31, 2025 243.12M
September 30, 2025 230.33M
June 30, 2025 228.36M
March 31, 2025 228.36M
December 31, 2024 220.42M
September 30, 2024 188.84M
June 30, 2024 188.82M
March 31, 2024 188.75M
December 31, 2023 174.99M
September 30, 2023 174.99M
June 30, 2023 174.44M
March 31, 2023 170.17M
December 31, 2022 170.09M
September 30, 2022 169.89M
June 30, 2022 169.75M
March 31, 2022 169.73M
December 31, 2021 169.48M
September 30, 2021 168.46M
June 30, 2021 167.04M
March 31, 2021 162.07M
December 31, 2020 153.10M
September 30, 2020 149.99M
Date Value
June 30, 2020 149.83M
March 31, 2020 149.82M
December 31, 2019 149.80M
September 30, 2019 149.79M
June 30, 2019 149.64M
March 31, 2019 149.39M
December 31, 2018 127.14M
September 30, 2018 126.88M
June 30, 2018 126.87M
March 31, 2018 126.87M
December 31, 2017 126.87M
September 30, 2017 115.80M
June 30, 2017 110.88M
March 31, 2017 110.86M
December 31, 2016 102.78M
September 30, 2016 102.77M
June 30, 2016 101.67M
March 31, 2016 94.89M
December 31, 2015 90.42M
September 30, 2015 82.04M
June 30, 2015 78.39M
March 31, 2015 78.32M
December 31, 2014 67.41M
September 30, 2014 68.29M
June 30, 2014 66.87M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Curis, Inc. 4.105M
Armata Pharmaceuticals, Inc. 37.19M
Voyager Therapeutics, Inc. 62.17M
Black Diamond Therapeutics, Inc. 57.47M
Invivyd, Inc. 295.63M